Nasdaq gnlx.

On September 26, an intriguing development occurred in the world of finance. Aladar Szalay, a prominent figure within Genelux (NASDAQ:GNLX), made a significant move by selling off 16,591 shares of the company. The transaction amounted to a staggering $462,000, as revealed in a recently filed Form 4 with the U.S. Securities and …GNLX Genelux Corporation Form 4 - Statement of changes in beneficial ownership of securities. SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF ...Genelux (NASDAQ: GNLX) is owned by 15.88% institutional shareholders, 5.64% Genelux insiders, and 78.48% retail investors. Aladar Szalay is the largest individual Genelux shareholder, owning 555,000.00 shares representing 2.08% of the company. Aladar Szalay's Genelux shares are currently valued at $6.21M.GNLX Genelux Corporation Form 4 - Statement of changes in beneficial ownership of securities. SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF ...12. 6. 2023 ... ... (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement for 900,000 shares of the Company's common ...

Genelux Co. ( NASDAQ:GNLX – Free Report) – Analysts at HC Wainwright issued their FY2023 earnings per share (EPS) estimates for shares of Genelux in a report released on Monday, November 27th ...Web

Market Activity. Market Activity->. Stocks; Options; Funds + ETFs; Indexes; Commodities; CryptocurrencyOct 13, 2023 · Price Target. $25.00. Profile Analyst Ratings Chart Competitors Earnings Financials Insider Trades Institutional Ownership Headlines SEC Filings Short Interest Social Media. Current. Insider Ownership. Percentage. 11.70%. Number Of.

Genelux Corporation (NASDAQ:GNLX) is a California based biotechnology firm that develops treatments for pancreatic, ovarian, and lung cancer. Its shares are rated Buy on average and analysts have ...NASDAQ GNLX opened at $11.10 on Monday. Genelux Co. has a twelve month low of $5.35 and a twelve month high of $40.98. Genelux Co. has a twelve month low of $5.35 and a twelve month high of $40.98.WESTLAKE VILLAGE, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that it will be added to the broad-market Russell 3000® Index and small-cap Russell 2000® at the conclusion of the 2023 Russell indexes annual reconstitution, …GNLX Genelux Corporation Form 4 - Statement of changes in beneficial ownership of securities. SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF ...WESTLAKE VILLAGE, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second ...

Follow. WESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of ...

Genelux Corporation (NASDAQ:GNLX) rose 18.4% to $23.99. Shengfeng Development Limited (NASDAQ:SFWL) gained 17.2% to $6.09. Dunxin Financial Holdings Limited (NYSE:DXF) climbed 16.8% to $1.73.

Oct 20, 2023 · Genelux Corporation (NASDAQ:GNLX) is a California based biotechnology firm that develops treatments for pancreatic, ovarian, and lung cancer. Its shares are rated Buy on average and analysts have ... Webull offers Genelux Corp stock information, including NASDAQ: GNLX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GNLX stock news, and many more online research tools to help you make informed decisions. Jan 27, 2023 · According to the issued ratings of 3 analysts in the last year, the consensus rating for Genelux stock is Buy based on the current 3 buy ratings for GNLX. The average twelve-month price prediction for Genelux is $25.00 with a high price target of $40.00 and a low price target of $10.00. Learn more on GNLX's analyst rating history. WESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) (“Genelux” or “the Company”), a late clinical-stage biopharmaceutical company focused on ...Genelux ( NASDAQ: GNLX) is a recently IPO-ed phase 3 stage cancer therapeutics company. Its business is designing “oncolytic viral immunotherapies that are designed to generate a personalized ...

WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the ...WebGenelux Corp. GNLX, +12.02% has set terms for its initial public offering, in which the California-based biotechnology company focused on treating difficult-to-treat tumors could be valued at up ...Genelux (NASDAQ:GNLX) and Janux Therapeutics (NASDAQ:JANX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, risk, profitability, analyst recommendations, dividends, media sentiment and valuation.Genelux Corporation (NASDAQ:GNLX) most popular amongst retail investors who own 57%, insiders hold 25%. Key Insights Significant control over Genelux by retail investors …Shares of Genelux Corporation ( GNLX 3.11%) were up by as much as 20.8% for the week on Thursday, according to data provided by S&P Global Market Intelligence. The healthcare company closed last ...WebIn terms of stock performance, immunotherapy developer Genelux (NASDAQ:GNLX) has been the hands-down winner, with shares up an impressive 417% from their IPO price as of Monday's close.WebNov 23, 2023 · Nelly Dodson. November 23, 2023. Business. Genelux Corp (NASDAQ:GNLX)’s traded shares stood at 76372.0 during the last session. At the close of trading, the stock’s price was $11.19, to imply an increase of 7.80% or $0.81 in intraday trading. The GNLX share’s 52-week high remains $40.98, putting it -266.22% down since that peak but still ...

0. Barclays PLC, a global financial services firm, recently acquired a new stake in Genelux Co. (NASDAQ:GNLX) during the first quarter of this year. According to its latest filing with the Securities and Exchange Commission (SEC), Barclays purchased 33,178 shares of Genelux’s stock, valued at approximately $920,000.Nasdaq. 14,305.03 +78.81 (+0.55%) ... the Company’s shares are expected to begin trading on the Nasdaq Capital Market under the ticker symbol “GNLX” on January 26, 2023 subject to final ...

WESTLAKE VILLAGE, Calif. , Sept. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that on September 11, 2023 , the Company’s Board of Directors (the “Board”) granted inducement awards consisting of non-qualified stock September 14, …Web10% least volatile stocks in US Market. 2.9%. Stable Share Price: GNLX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week. Volatility Over Time: GNLX's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.Webull offers Genelux Corp stock information, including NASDAQ: GNLX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GNLX stock news, and many more online research tools to help you make informed decisions. In terms of stock performance, immunotherapy developer Genelux (NASDAQ:GNLX) has been the hands-down winner, with shares up an impressive 417% from their IPO price as of Monday's close.add_box. WESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of ...WebJan 21, 2023 · Companies that could price their IPOs and start trading include Genelux (NASDAQ:GNLX), Elate Group , MorningStar Partners , and Syla Technologies . Intel earnings ...

FN Media Group Presents USA News Group News Commentary . Vancouver, BC – October 11, 2023 – USA News Group – Researchers are becoming increasingly concerned with the rates of cancer on the rise among people under 50. A recent study found a nearly 80% global increase in the number of under-50s getting diagnosed with cancer …

Nasdaq provides visual representation of analyst expected earnings growth. Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the ...

Nov 27, 2023 · American International Group Inc. bought a new position in Genelux Co. (NASDAQ:GNLX – Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 1,332 shares of the company’s stock, valued at approximately $44,000. A number of other institutional investors also recently modified their […] WESTLAKE VILLAGE, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) and TVAX Biomedical, Inc. today announced that the United States Patent and Trademark Office granted ...WESTLAKE VILLAGE, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) and TVAX Biomedical, Inc. today announced that the United States Patent and Trademark Office granted ...WebWESTLAKE VILLAGE, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second ...WebFind the latest Financials data for Genelux Corporation Common Stock (GNLX) at Nasdaq.com.WebAug 28, 2023 · WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the ... In terms of stock performance, immunotherapy developer Genelux (NASDAQ:GNLX) has been the hands-down winner, with shares up an impressive 417% from their IPO price as of Monday's close.WebGenelux Corporation (NASDAQ:GNLX) 10% owner Aladar Szalay disclosed after the bell on Oct. 25 the sale of an aggregate of 49,987 shares priced at $19.97 apiece for about $998,365 on Oct 23.Genelux | 726 followers on LinkedIn. Genelux Corporation (NASDAQ: GNLX) is a late clinical-stage biotechnology company focused on improving the lives of patients affected by difficult-to-treat solid tumors. Our ChoiceTM Discovery Platform is the foundation of our oncolytic immunotherapy development, having produced over 500 different versions of …GNLX Genelux Corporation Form 4 - Statement of changes in beneficial ownership of securities. SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF ...

Jul 28, 2023 · Shares of Genelux ( GNLX -7.61%) were up 14.8% for the week, as of 9:30 a.m. ET Friday, according to data provided by S&P Global Market Intelligence. The clinical-stage biotech company's stock ... Genelux Corporation Common Stock (GNLX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Genelux Corporation (NASDAQ:GNLX) gained 12.9% to $30.82. Franchise Group, Inc. (NASDAQ:FRG) jumped 11.8% to $25.44. Franchise Group revealed the receipt of an unsolicited non-binding proposal to ...WESTLAKE VILLAGE, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology …Instagram:https://instagram. arm stock price todaypre market high volume stockstrsgxcowz etf holdings On September 18, 2023, John Thomas, a director at Genelux Corp ( NASDAQ:GNLX ), sold 6,667 shares of the company. This move comes amidst a year where the insider has sold a total of 6,667 shares ... vym comparecrowdstrike stock forecast Genelux ( NASDAQ: GNLX) said it has received fast-track status from the FDA for its Olvi-Vec program for the treatment of platinum resistant/refractory ovarian cancer. The company is currently ...The latest price target for . Genelux (NASDAQ: GNLX) was reported by Maxim Group on September 12, 2023.The analyst firm set a price target for $40.00 expecting GNLX to rise to within 12 months (a ... quien es george soros WESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of 1,665,247 ...WebJun 29, 2023 · WESTLAKE VILLAGE, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) and TVAX Biomedical, Inc. today announced that the United States Patent and Trademark Office granted ...